🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
1,930

Quick answer

1,930 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 8901279

    Humanized antibodies with anti-tumor activity

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8883161

    Fusion polypeptide against EB virus-induced tumor and colicin Ia mutant

    PROTEIN DESIGN LAB, LTD. · Granted Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8883500

    Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy

    Northwestern University · Granted Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8877718

    Antiinfective and antitumoral compounds isolated from tropical lianas

    Julius-Maximilians-Universitat Wurzburg · Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8877204

    Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes

    University of Connecticut Health Center · Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8877765

    Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8865873

    Internalizing human monoclonal antibodies targeting prostate cancer cells in situ

    The Regents of the University of California · Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8865748

    Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer

    Akebia Therapeutics, Inc. · Granted Tue Oct 21 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8859527

    Inclusion complex of deoxypodophyllotoxin of cyclodextrin, preparation method, use for treatment of cancer thereof

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8853277

    Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8846629

    Id-1 and Id-2 genes and products as therapeutic targets for treatment of breast cancer and other types of carcinoma

    The Regents of the University of California · Granted Tue Sep 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8840886

    Method of treating cancer with DLL4 antagonist and chemotherapeutic agent

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8835613

    β-mannosylceramide and stimulation of NKT cell anti-tumor immunity

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8835493

    Oligo-benzamide compounds for use in treating cancers

    The Board of Regents of the University of Texas System · Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8834938

    Use of arsenic for cancer therapy protection

    The Board of Regents of the University of Texas System · Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8835167

    Humanized anti-tag 72 CC49 for diagnosis and therapy of human tumors

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8829025

    Anti-cancer compounds

    Northwestern University · Granted Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8822196

    Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8821880

    Methods and agents for the diagnosis and treatment of hepatocellular carcinoma

    China Synthetic Rubber Corporation · Granted Tue Sep 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8816059

    Method for predicting and detecting tumor metastasis

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8815830

    Nucleosides with antiviral and anticancer activity

    Regents of the University of Minnesota · Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8815240

    Methods and agents for the diagnosis and treatment of hepatocellular carcinoma

    China Synthetic Rubber Corporation · Granted Tue Aug 26 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8809291

    Id-1 gene and gene products as therapeutic targets for treatment of breast cancer and other types of carcinoma

    The Regents of the University of California · Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8808698

    Methods for inhibition of lymphangiogenesis and tumor metastasis

    The Regents of the University of California · Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8809502

    Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8802689

    Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

    The Regents of the University of California · Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8802090

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    PRECISION BIOLOGICS, INC. · Granted Tue Aug 12 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8795738

    Use of arsenic for cancer therapy protection

    The Board of Regents of the University of Texas System · Granted Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8795964

    GRM3 mutations and use thereof for the diagnosis and treatment of melanoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8790878

    Diagnosis and treatment of breast cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8790869

    Renal cell carcinoma biomarkers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8785409

    Compounds having anti-adhesive effects on cancer cells

    The Board of Regents of the University of Texas System · Granted Tue Jul 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8785373

    Agents capable of downregulating an MSF-A-dependent HIF-1alpha and use thereof in cancer treatment

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Jul 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8779151

    Orally bioavailable caffeic acid related anticancer drugs

    The Board of Regents of the University of Texas System · Granted Tue Jul 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8778608

    CA9 gene single nucleotide polymorphisms predict prognosis and treatment response of metastatic renal cell carcinoma

    The Regents of the University of California · Granted Tue Jul 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8772238

    Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Jul 08 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8765935

    Nucleosides with antiviral and anticancer activity

    Regents of the University of Minnesota · Granted Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8759006

    PSCA: prostate stem cell antigen and distinguishing androgen receptor negative prostate cancer from benign prostatic hyperplasia

    The Regents of the University of California · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8754046

    MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8754124

    Oligo-benzamide compounds and their use in treating cancers

    The Board of Regents of the University of Texas System · Granted Tue Jun 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8748114

    ZAP-70 expression as a marker for chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL)

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Jun 10 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8741306

    Kidney specific tumor vaccine directed against kidney tumor antigen G-250

    The Regents of the University of California · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8741315

    Methods of treating tumors in immune-privileged sites

    The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8742141

    Inhibition and treatment of prostate cancer metastasis

    Northwestern University · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8734799

    Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer

    The Regents of the University of California · Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8735358

    Methods for treating cancer by regulation of tumor necrosis factor-alpha

    The Regents of the University of Colorado, a Body Corporate · Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8735082

    Gene signature for predicting prognosis of patients with solid tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8735075

    Cancer screening by detection of ultrastructural and molecular markers

    Northwestern University · Granted Tue May 27 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

1,930 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.